3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
13
Gastrointestinal Stromal Tumors
12
Leukemia, Myeloid, Chronic-Phase
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Leukemia
3
Neoplasms
2
Melanoma
2
Burkitt Lymphoma
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Thyroid Cancer, Papillary
1
Squamous Cell Carcinoma of Head and Neck
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
1
Philadelphia Chromosome
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Lymphangioleiomyomatosis
1
Leukemia, Myeloid
1
Leukemia, Biphenotypic, Acute
1
Hypereosinophilic Syndrome
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Graft vs Host Disease
1
Digestive System Neoplasms
1
Desmoid Tumors
1
Dermatofibrosarcoma
1
Congenital Bone Marrow Failure Syndromes
1
Chordoma
1
Carcinoma, Adenoid Cystic
1
Interventions
Nivolumab
11
pembrolizumab
10
Ipilimumab
9
Cyclophosphamide
6
tebentafusp
5
Interleukin-2
4
Blood Specimen Collection
4
fludarabine phosphate
3
fludarabine
3
Specimen Handling
3
Radiosurgery
3
Melphalan
3
Magnetic Resonance Spectroscopy
3
relatlimab
2
lenvatinib
2
cemiplimab
2
binimetinib
2
aflibercept
2
Surveys and Questionnaires
2
Dacarbazine
2
Crizotinib
2
Carmustine
2
Biopsy
2
ulixertinib
1
trametinib
1
sargramostim
1
ruxolitinib
1
omipalisib
1
olaparib
1
lifileucel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uveal Melanoma
×
Imatinib Mesylate
×
1 year
×
Clear all
NCT01046487
2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1
Completed
26 enrolled